The pure form of familial dilated cardiomyopathy (DCM) is mainly caused by mutations in genes encoding sarcomeric proteins. Previous measurements using recombinant proteins suggested that DCM mutations in thin filament proteins decreased myofibrillar Ca 2+ sensitivity, but exceptions were reported. We re-investigated the molecular mechanism of familial DCM using native proteins.
Introduction
Idiopathic dilated cardiomyopathy (DCM) has a prevalence of 1 in 2500 and is a common cause of heart failure, especially in the young. The disease is characterized by an unexplained left ventricular dilation and impaired systolic function and is believed to be caused by genetic mutations in up to 50% of cases. Typical echocardiographic criteria are left ventricular end-diastolic diameter .117% of expected for age and body weight and fractional shortening ,25%. Mutations associated with the familial DCM phenotype have been found in genes encoding proteins located in a wide range of organelles of the cardiomyocyte that include the sarcomeres, Z-discs, costameres, and cytoskeleton. 2, 3 The molecular mechanisms proposed for familial DCM include defects in force production, force transmission, and stress-dependent cell signalling. This diversity contrasts with hypertrophic cardiomyopathy, where there is a strong association between mutations in sarcomeric proteins and higher myofibrillar Ca 2+ sensitivity. 4, 5 Mutations in the genes for the force generating proteins of the cardiac muscle sarcomere, actin (ACTC), myosin (MYH7), tropomyosin (TPM1), troponin I (TnI) (TNNI3), troponin T (TNNT2), troponin C (TNNC1), and titin (TTN) were observed to be associated with a specific 'pure' cardiac phenotype without any additional syndromes, such as hypertrophy, conduction disease, or dystrophy and with a high prevalence in young people. 1,6 -8 The common phenotype of mutations in sarcomeric proteins with related functions suggests that for this subset of DCM-causing mutations there could be a common causative molecular mechanism. Initial studies of DCM-causing mutations in sarcomeric proteins at the myofilament and myofibrillar levels suggested that there could be a common defect in Ca 2+ regulation, with a decrease in myofibrillar Ca 2+ sensitivity, Ca 2+ -binding affinity for troponin C, and a slower cross-bridge cycling rate at maximally activating [Ca 2+ ], and this was proposed to be sufficient to induce the DCM phenotype. 2, 9, 10 However, exceptions to this pattern of results have been reported: for example, a-tropomyosin E54K did not change Ca 2+ sensitivity and increased Ca 2+ -binding affinity, troponin T (cTnT) DK210
increased Ca 2+ sensitivity at 100% but decreased Ca 2+ sensitivity when present at 50% of cTnT 9, 10 and the cardiac a-actin E361G mutation did not alter Ca 2+ sensitivity. 11 Further exceptions have been recently reported. 12, 13 The original studies mostly used recombinant, unphosphorylated troponin subunits and did not take into account the effect of troponin I (cTnI) phosphorylation in modulating Ca 2+ sensitivity. In normal heart muscle, protein kinase A (PKA) phosphorylates cTnI which leads to a two-to three-fold reduction in Ca 2+ sensitivity and an increased rate of Ca 2+ dissociation from troponin C (cTnC); this process plays a key role in the lusitropy induced by b-adrenergic stimulation in the heart. 14 -16 We have developed methodologies for measuring both myofilament Ca 2+ sensitivity (by quantitative in vitro motility assay) and cTnI phosphorylation (by phosphate affinity SDS-PAGE) in troponin from human and mouse hearts. 17, 18 Studies on two DCM-causing mutations, cTnC G159D (TNNC1) and cardiac a-actin E361G (ACTC) found that isolated mutant thin filament Ca 2+ sensitivity was not related to the level of phosphorylation of cTnI and a similar phenomenon was noted in other experimental systems. 11,19 -21 On the basis of these results, we proposed an alternative mechanism for the familial DCM phenotype: DCM mutations uncouple cTnI phosphorylation from the change in myofilament Ca 2+ sensitivity and blunt the heart's response to b-adrenergic stimulation, leading to a reduced cardiac reserve with consequent contractile dysfunction under stress, leading to DCM. 4 This hypothesis is currently based on studies of only two mutations which may be special cases. In this manuscript, we have investigated Ca 2+ sensitivity and its modulation by cTnI phosphorylation in a further six DCM-causing mutations, including a unique human heart sample with a previously characterized DCM mutation in the TNNI3 gene, cTnI K36Q 22 ; two mutations in cTnT (TNNT2 gene) extracted from transgenic mouse hearts (R141W and DK210). 23, 24 Three mutations in the TPM1 gene coding for a-tropomyosin E40K, E54K, and the recently reported D230N 25, 26 were expressed in a baculovirus/ Sf9 system so as to include native post-translational modifications that can affect function. 9, 10, 27 Taken together with previous measurements, we show that myofibrillar Ca 2+ sensitivity is not correlated with the DCM phenotype, while Ca 2+ sensitivity is uncoupled from TnI phosphorylation in all cases of DCM due to mutations in thin filament proteins.
Methods

Sources of contractile proteins
Troponin was isolated from 100 mg of heart muscle using an anti-cTnI monoclonal antibody affinity column as described by Messer et al.
18
Control troponin was obtained from eight human donor heart samples. The heart donors had no history of cardiac disease, and normal ECG and ventricular function were obtained when no suitable transplant recipient was found. The heart sample with the cTnI (TNNI3) K36Q mutation, described by Carballo et al. 22 
Quantitative in vitro motility assay
Thin filaments were reconstituted with 10 nM rabbit skeletal muscle a-actin (labelled with TRITC phalloidin), 32 human heart muscle tropomyosin (40 -60 nM), and troponin (20 -60 nM) to study Ca 2+ regulation of filament motility by the quantitative in vitro motility assay. 18, 33 Thin filament movement over a bed of immobilized rabbit fast skeletal muscle heavy meromyosin (100 mg/mL) was compared in paired motility cells in which troponin varied by a single factor (mutation or phosphorylation state). Filament movement was recorded and analysed as previously described, 34 yielding two parameters, the fraction of filaments moving and the speed of moving filaments. In our motility system, both these parameters are regulated by Ca 2+ . The fraction motile changes from ,0.1 to .0.8 in the range 1 nmol/L to 3.7 mmol/L free Ca 2+ .
The Ca 2+ -dependent change of sliding speed was less and more variable (0 -50% change), as previously noted. 3. Results
Effect of DCM-causing mutations on myofilament Ca 21 -sensitivity
The quantity of mutant protein expressed in mouse or human hearts was determined by mass spectrometry (see Supplementary material online, Part SC). Troponin from cTnT R141W mice contained 60% mutant troponin, troponin from heterozygous cTnT DK210 KI mice contained 40% mutant troponin, while troponin from homozygous cTnT DK210 KI mice contained 100% mutant troponin. In the human sample with the cTnI K36Q mutation, both wild-type and mutant sequences were detected and we estimated that .86% of the cTnI was present as the mutant form (see Supplementary material online, Table SA ). The native cTnI phosphorylation levels of the mutant mouse troponins were the same as wild-type littermates (range 1.1 -1.3 molsPi/mol cTnI) but the TNNI2 K36Q troponin, obtained from a Figure 2A and shown in Supplementary material online, Table SA .
(A) Thin filaments containing human heart troponin with TnI K36Q mutation (PKA treated) compared with donor heart troponin; human heart tropomyosin; and rabbit skeletal muscle a-actin. (B) Thin filaments containing transgenic TnT R141W (40%) mouse troponin compared with non-transgenic mouse troponin; human heart tropomyosin; and rabbit skeletal muscle a-actin. (C) Thin filaments containing heterozygous TnT DK210 (60%) KI mouse troponin compared with non-transgenic mouse troponin; human heart tropomyosin; and rabbit skeletal muscle a-actin. (D) Thin filaments containing a-tropomyosin E40K (100%) compared with wild-type tropomyosin (both expressed in the baculovirus/Sf9 system); human donor heart troponin and rabbit skeletal muscle a-actin. (E) Thin filaments containing a-tropomyosin E54K (100%) compared with wild-type tropomyosin (both expressed in the baculovirus/Sf9 system); human donor heart troponin; and rabbit skeletal muscle a-actin. (F ) Thin filaments containing a-tropomyosin D230N (100%) compared with wild-type tropomyosin (both expressed in the baculovirus/Sf9 system); human donor heart troponin; and rabbit skeletal muscle a-actin.
heart transplant, had a lower level of phosphorylation than donor heart (0.33 + 0.10 compared with 1.60 + 0.04 molsPi/mol cTnI in donor heart) and was treated with PKA to make the phosphorylation level similar to donor heart ( Figure 2 and Table 1 ).
18,21 Figure 3 shows a titration of the EC 50 , measured by in vitro motility assay, against the level of TnI phosphorylation in thin filaments containing human cardiac troponin. To reduce cTnI phosphorylation, while leaving all the other troponin subunits unaltered, we exchanged recombinant, unphosphorylated cTnI into donor heart troponin, and to increase the level of phosphorylation, we treated troponin with PKA. EC 50 increased (Ca 2+ sensitivity decreased) with increasing bis-phosphorylation of cTnI up to 1.5 molsPi/mol cTnI, but was unchanged at higher levels of phosphorylation. It was previously noted that the Ca 2+ sensitivity of thin filaments containing the DCM-causing mutants cardiac a-actin E361G or cTnC G159D was independent of the level of cTnI phosphorylation. 11, 19, 21 We, therefore, tested whether this 'uncoupling' of the Ca 2+ sensitivity -TnI phosphorylation relationship was also a property of DCM-causing mutations in cTnI, cTnT, and a-tropomyosin. The Ca 2+ sensitivity of thin filaments containing phosphorylated cTnI (native phosphorylation levels were 1.5 molsPi/mol cTnI) and unphosphorylated cTnI (,0.3 molsPi/mol cTnI) was compared. Unphosphorylated cTnI was obtained by treating wild-type and mutant mouse or human heart troponin with a phosphatase. The three tropomyosin mutants were tested with natively phosphorylated and unphosphorylated human donor heart troponin. The native phosphorylation level of cTnI K36Q troponin was lower than donor heart troponin; accordingly this was treated with either phosphatase to reduce phosphorylation or PKA to increase phosphorylation levels. Table 1 lists the measured phosphorylation levels and EC 50 of the phosphorylated/unphosphorylated thin filament pairs we studied. Representative experiments are shown in Figure 4 and results from several replicates are summarized in Figure 2B .
In contrast to native thin filaments, when we compared the Ca 2+ sensitivity of thin filaments containing DCM-causing mutations in the phosphorylated and unphosphorylated states, there was no difference in Ca 2+ sensitivity for any of them ( Figures 2B and 4 and Table 1 ). The uncoupling phenomenon is expected to require Figure 2 The effect of DCM-causing mutations on thin filament The results obtained with eight DCM-causing mutations and wild-type human and mouse troponin controls are shown. EC 50 for Ca 2+ regulation of the fraction motile parameter of phosphorylated and unphosphorylated thin filaments moving in the in vitro motility assay and the ratios of EC 50 P/unP were compared. Representative individual experiments are shown in Figure 4 and the mean results from several replicate experiments are shown in Figure 2 . Het, heterozygous; homo. homozygous. Mean and standard error for n independent measurements are shown with P-value (student t test). Troponin I phosphorylation levels were measured by phosphate affinity SDS -PAGE. **P , 0.01 a Dyer et al.
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DCM mutations abolish effects of troponin I phosphorylation substoichiometric amounts of mutant proteins, since cTnT R141W and heterozygous DK210 were observed to be uncoupled with 60 and 40% of mutant protein in the thin filaments, respectively. We demonstrated this directly using the a-tropomyosin E40K mutant. The Ca 2+ sensitivity of thin filaments containing phosphorylated and unphosphorylated donor heart troponin was compared over a range of E40K:wild-type a-tropomyosin ratios ( Figure 5A ). It was observed that there was significant uncoupling with just 12.5% mutant a-tropomyosin and complete uncoupling was observed at 50% mutant protein. The wild-type:mutant ratio that produced complete uncoupling corresponds approximately to the actual ratio of wild-type to mutant found in the DCM-mutant troponin samples.
Discussion
Previous experiments, mostly using recombinant DCM-causing mutated proteins, suggested that the common functional abnormality of DCM-causing mutations in thin filament proteins was a lower Ca 2+ sensitivity and slower maximally activated unloaded cross-bridge turnover rate. 2, 9, 10, 35 However, when we tested eight DCM-causing mutations by the in vitro motility assay using natively phosphorylated proteins we were unable to confirm this. Different DCM-causing mutations could increase, decrease or have no effect on Ca 2+ sensitivity when studied with native proteins (Figure 2) . Moreover, in five of the eight mutations examined, including the novel TPM1 D230N mutation, a comparison of our current data with previously published data, summarized in Table 2 , showed that the direction of change of Ca 2+ sensitivity could be different for a single mutation depending on the isoform, 21 expression level, 9 and post-translational modifications of the partner proteins. 11 This variability indicates that a decrease in myofilament Ca 2+ sensitivity is unlikely to be the primary effect of DCM-causing mutations; our results did, however, suggest that troponin phosphorylation plays a role in the DCM phenotype.
DCM-causing mutations in thin filament proteins uncouple Ca 21 sensitivity changes from TnI phosphorylation
Phosphorylation of TnI by PKA is well known to modulate myofibrillar Ca 2+ sensitivity, 15, 18 as demonstrated for our assay system by the titration of EC 50 against TnI bis-phosphorylation (Figure 3 ), but we observed that there was no modulation of myofibrillar Ca 2+ sensitivity by PKA-dependent phosphorylation of cTnI in thin filaments containing DCM-causing mutations. This 'uncoupling' was observed in every DCM mutation we tested, independent of the gene mutated or the origin of the mutated protein (recombinant or native, from mouse or human heart, see Figure 2 and Table 1 ). Moreover, uncoupling needed only 50% mutant protein, a ratio that corresponds to the amount of mutant protein expressed in heart tissue of DCM patients ( Figure 5A ). For the ACTC and the three TPM1 mutations, we can confidently conclude that the uncoupling is a direct effect of the mutation, since the troponin used in the tests is from human donor hearts that showed a phosphorylation-dependant Ca 2+ -sensitivity change with wild-type a-actin and a-tropomyosin. Uncoupling has also been reported for a DCM-causing mutation in cTnI and several mutations in cTnC. 19, 20, 36 4. Figure 5B ). It is interesting to note that, in addition to DCM, uncoupling has also been reported for mutations in cardiac a-actin and cTnI that cause hypertrophic cardiomyopathy, 38, 39 and as a secondary abnormality in troponin isolated from an interventricular septum of patients with hypertrophic obstructive cardiomyopathy, where it is not mutation related. 40, 41 Thus, uncoupling may be a widespread phenomenon in pathological heart muscle.
The physiological significance of uncoupling
In the normal heart, b-adrenergic stimulation leads to activation of PKA and increased phosphorylation of cTnI. The resulting decrease in myofilament Ca 2+ sensitivity and the associated increase in the rate of Ca 2+ dissociation from cTnC is a key component of the lusitropic response, since Ca 2+ release is likely to be a rate limiting step for relaxation in vivo. 16 We can measure the modulation of Ca 2+ sensitivity by TnI phosphorylation in our in vitro motility assay system ( Figure 3 ) and demonstrate that the modulation is uncoupled by DCM-causing mutations (Figure 2) . We have also demonstrated uncoupling of the Ca 2+ sensitivity of isometric force production in phosphorylated and unphosphorylated single myofibrils with the a-actin E361G DCM-causing mutation. 42 Faster relaxation (lusitropy) is a pre-requisite for the faster heart rate and increased contractile force (inotropy) induced by b-adrenergic stimulation. Therefore, it is likely that uncoupling due to DCM-causing mutation blunts the response to b-adrenergic stimulation, leading to a reduced cardiac reserve. 43 A significantly reduced response to acute b-adrenergic agonists has been demonstrated in several DCM-mutant mice (ACTC E361G, TNNT2 DK210, and TPM1 E54K). 21, 24, 44 The resulting contractile dysfunction under stress would predispose the heart to DCM in the long term as has been found with DCM-mutant transgenic mice. 45 Mutation-dependent decreases in absolute myofibrillar Ca 2+ sensitivity may also contribute, but the lack of a correlation ( Figures 1 and 2) indicates that they are not necessary for the DCM phenotype. Figure 2B and shown, together with phosphorylation levels measured in the samples used for these experiments, in Table 1 . The points + SEM are the mean of four determinations of fraction motile measured in one motility cell. The curves are fits of the data to the Hill equation. (A) Phosphorylated (PKA treated) and unphosphorylated human heart troponin with TnI K36Q mutation; human heart tropomyosin and rabbit skeletal muscle a-actin. (B) Natively phosphorylated and unphosphorylated transgenic TnT R141W (40%) mouse troponin; human heart tropomyosin; and rabbit skeletal muscle a-actin. (C) Natively phosphorylated and unphosphorylated heterozygous TnT DK210 (60%) KI mouse troponin; human heart tropomyosin; and rabbit skeletal muscle a-actin. (D) Natively phosphorylated and unphosphorylated human donor heart troponin with a-tropomyosin E40K (100%) and rabbit skeletal muscle a-actin. (E) Natively phosphorylated and unphosphorylated human donor heart troponin with a-tropomyosin E54K (100%) and rabbit skeletal muscle a-actin. (F ) Natively phosphorylated and unphosphorylated human donor heart troponin with a-tropomyosin D230N (100%) and rabbit skeletal muscle a-actin. Figure 5 (A) The effect of changing the ratio of wild-type: E40K mutant a-tropomyosin on the relationship between Ca 2+ -sensitivity and cTnI phosphorylation. EC 50 was compared, as in Figure 4E , with natively phosphorylated and unphosphorylated human donor heart troponin, rabbit skeletal muscle a-actin and a-tropomyosin consisting of varying ratios of wild-type and E40K a-tropomyosin. The ratio of EC 50 for natively phosphorylated and unphosphorylated thin filaments is plotted. The original data are shown in Supplementary material online, Part SB1. The ratio was 2.9 for wild-type a-tropomyosin; a ratio of one indicates complete uncoupling (dotted line). The arrows indicate the measured fraction of mutant protein in heterozygous cTnT DK210 (40%), cTnC G159D (45%), a-actin E361G (50%), and cTnT R141W (60%) hearts, respectively, (see Supplementary material online, SC). 
